Work

62P Ecto-CRT induction of NKp46 surface expression increases osimertinib-resistant lung cancer’s sensitivity to NK cells

Year: 2024

Type: article

Abstract: Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) have dramatically changed lung cancer treatment modalities and improved EGFR-mutated non-small cell lung cancer (NSCLC) patients’ prognosis over the past two decades. Third-generation EGFR-TKI, Osimertinib, has resulted in impressive success both in the first-line treatment setting and as a salvage therapy in the presence of the T790M secondary mutation. However, most patients inevitably develop resistance, with therapeutic options limited to platinum-based chemotherapy.

Source: Immuno-Oncology Technology

DOI: 10.1016/j.iotech.2024.100873

Authors: S. Chen, Y. Jounaidi

Institutions: Hangzhou Cancer Hospital, Harvard University, Massachusetts General Hospital

Language: English

Topic: Immune Cell Function and Interaction

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,170